PHOFAY ACNE SPOT TREATMENT Cream

Manufacturer
Longway Technology(Guangzhou) Co., Ltd.
Effective date
2025-08-23
Label type
HUMAN OTC DRUG LABEL
Version
1
Source
full-release
Hydrated at
2026-06-01 01:12:05

Label at a glance#

ProductPHOFAY ACNE SPOT TREATMENT Cream
Active ingredientSALICYLIC ACID
Label structure9 sections

Label contents#

Full prescribing information#

OTC - ACTIVE INGREDIENT SECTION

SALICYLIC ACID1.08%

OTC - KEEP OUT OF REACH OF CHILDREN SECTION

lf Swallowed, Get Medica Help or Contact a Poison Control Center right away

WARNINGS SECTION

For external use only
When using this product

skin irritation and dryness is more likely to occur if you use another topical acne medication at the same time. lf irritation occurs, only use one topical acne medication at a time.

DOSAGE & ADMINISTRATION SECTION

Directions
clean the skin thoroughly before applying this product

cover the entire affected area with a thin layer one to three times daily

because excessive drying of the skin may occur, start with one application daily, then gradually increase to two or three times daily if needed or as directed by a doctor

if bothersome dryness or peeling occurs, reduce application to once a day or every other day.

INACTIVE INGREDIENT SECTION

Water, Butylene Glycol, Caprylic/Capric Triglyceride,Cetyl Ethylhexanoate, Propylene Glycol, Dimethicone Cetearyl Alcohol, C14-22 Alcohols, Glyceryl Stearate,Niacinamide, Betaine,PEG-100 Stearate, 1,2-Hexanediol,Hydroxyacetophenone, Sodium Hydroxide, PEG-40 Hydrogenated Castor Oil, C12-20 Alkyl Glucoside,Acrylates/C10-30 Alkyl Acrylate Crosspolymer, Xanthan Gum,Centella Asiatica Root Extract, Menthol, Dipotassium Glycyrrhizate, Citric Acid, lron Oxides (Cl 77492)

OTHER SAFETY INFORMATION

protect the product in this container from excessive

heat and direct sun

OTC - PURPOSE SECTION

Acne treatment

INDICATIONS & USAGE SECTION

For the treatment of acne
Reduces the number of acne blemishes

Helps prevent the development of new acne pimples

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

PHOFAY ACNE SPOT TREATMENT CREAMPHOFAY ACNE SPOT TREATMENT CREAM

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
2722593salicylic acid 1.08 % Topical CreamPSN1
2722593salicylic acid 10.8 MG/ML Topical CreamSCD1
2722593salicylic acid 1.08 % Topical CreamSY1

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
d1c9d1af-bddd-448d-86f7-69052b7d5b47Product name120220627
dea2eded-d1e7-46bb-9a3d-f8dc20de6277Product name120190408

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
85161-132-01PHOFAY ACNE SPOT TREATMENT Cream1 g in 1 BOTTLECREAM11
85161-132-01PHOFAY ACNE SPOT TREATMENT Cream1 in 1 BOXCREAM11

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 26 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
85161-13285161-132-01

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 25 matching rows.

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
PHOFAY ACNE SPOT TREATMENT CreamSALICYLIC ACIDLongway Technology(Guangzhou) Co., Ltd.3d0511f6-168b-5377-e063-6294a90a3ca92025-08-23WarningsExact identifier
ndc (package): 85161-132-01
ndc (product): 85161-132
ndc11 (package): 85161013201
spl id: 3d0511f6-168c-5377-e063-6294a90a3ca9
spl set id: 3d0511f6-168b-5377-e063-6294a90a3ca9

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.